Should you buy Axsome Therapeutics stock now?
No, the technical signal for Axsome Therapeutics is currently Sell. Axsome Therapeutics trades at $174.34 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -9.080 with falling momentum (signal: -6.658); RSI is at 25.9 (oversold), which could point to a potential buying opportunity; the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $284.63 points to 63.3% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Axsome Therapeutics stock?
The average analyst price target for Axsome Therapeutics is $284.63. The current price is $174.34, which gives an upside of 63.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $256.17 and $313.09.
Is Axsome Therapeutics a dividend stock?
No, Axsome Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Axsome Therapeutics stock?
Axsome Therapeutics is rated as a stock in the risk category Moderate. the annual standard deviation is 43.8%, which classifies the stock as Moderate. In addition, an RSI of 25.9 signals oversold (potential bottom).
Is Axsome Therapeutics overvalued?
No, Axsome Therapeutics is considered undervalued based on the analyst price target (63.3% upside). Axsome Therapeutics has the following valuation ratios: a P/S ratio of 12.1, a P/B ratio of 121.6. The analyst price target suggests that the stock is undervalued by 63.3%.
Is Axsome Therapeutics overbought?
No, Axsome Therapeutics is actually oversold with an RSI of 25.9 (below 30). The technical indicators show: RSI is at 25.9 (below the 30 mark), which actually signals the price is oversold – the opposite of overbought. In addition, the price is 12.1% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish). IMPORTANT: The stock is oversold in a downtrend. A low RSI in a downtrend is NOT a buy signal – the price can keep falling. Wait for a trend reversal before buying.
When is the next Axsome Therapeutics earnings report?
Axsome Therapeutics reports its next earnings on November 2, 2026. The stock currently trades at $174.34. The RSI is at 25.9, so the report can reinforce the current technical trend.
Is Axsome Therapeutics shorted?
Yes, Axsome Therapeutics is shorted with 9.3% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Axsome Therapeutics stock?
No, insiders are not buying Axsome Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 12,624,805 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 62,491,060 $ sold. Active sellers include Jacobson Mark L., TABUTEAU HERRIOT, JEFFS ROGER and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Axsome Therapeutics a good stock?
Based on our total score, Axsome Therapeutics is rated as a disastrous stock with a total score of 15 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 5/100, Quality: 11/100, Momentum: 30/100. In addition: analysts see 63.3% upside to the price target; technical signal: Sell. Whether Axsome Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Axsome Therapeutics stock?
The outlook for Axsome Therapeutics based on current data: the average analyst price target is $284.63 (+63.3%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Nov 2, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Axsome Therapeutics stock falling?
Axsome Therapeutics is falling right now. The technical indicators show: the price is 12.1% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 9.3% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Axsome Therapeutics go?
The average analyst price target for Axsome Therapeutics is $284.63, which corresponds to a potential gain of 63.3% from the current price of $174.34. The stock has traded between $117.30 and $260.19 over the last 52 weeks. The price is 33.0% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Axsome Therapeutics fall?
The stock has traded as low as $117.30 over the last 52 weeks — that is 32.7% below the current price of $174.34. The biggest decline (drawdown) in the same period was 54.9% from high to low. Within a year, the price typically swings about ±43.8% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Axsome Therapeutics do?
Axsome Therapeutics (AXSM) is a biopharmaceutical company. It develops and sells medicines for brain and nervous system disorders. It makes money by selling products that are already approved and available to patients.
Its main products include:
- **Auvelity**, used to treat... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Axsome Therapeutics as an investment.
Did Axsome Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Axsome Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Axsome Therapeutics making money or losing money?
No, Axsome Therapeutics is currently not making money — the company is losing money with a negative profit margin of -24.7%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Axsome Therapeutics go bankrupt?
The bankruptcy risk of Axsome Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -5.91 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 897% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Axsome Therapeutics have a lot of debt?
Yes, Axsome Therapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 897%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
